The relation between acquired resistance of T790M mutation after EGFR-TKI and TP53 mutation in a biopsy tissue before EGFR-TKI

The relation between acquired resistance of T790M mutation after EGFR-TKI and TP53 mutation in a biopsy tissue before EGFR-TKI - The relation between acquired resistance of T790M mutation after EGFR-TKI and TP53 mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041476

Enrollment

Registered

2020-08-21

Start date

2020-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Daiagnosis of NSCLC by tissue biopsy before initial treatment NSCLC patient who was treated by EGFR-TKI as a first line chemotherapy

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Evaluate the relation between acquired resistance of T790M mutation after EGFR-TKI and TP53 mutation in a biopsy tissue before EGFR-TKI	—

Countries

Japan

Contacts

Public ContactMotohiro Tamiya

Osaka International Cancer Institute Thoracic Oncology

moto19781205@yahoo.co.jp06-6945-1181

Outcome results